More about

Car T-Cell Therapy

News
April 19, 2022
11 min read
Save

COVID-19 prevention must extend beyond vaccines for patients receiving cell therapies

COVID-19 prevention must extend beyond vaccines for patients receiving cell therapies

Infection mitigation with vaccines is essential for patients with hematologic malignancies because they are at increased risk for severe infection, hospitalization and mortality if they contract COVID-19.

News
April 14, 2022
7 min read
Save

From referral to infusion: Accelerating the CAR-T process

From referral to infusion: Accelerating the CAR-T process

There are many frustrating aspects to a cancer diagnosis.

News
April 12, 2022
2 min read
Save

Certain genetic patterns may predict response to CAR-T for acute lymphoblastic leukemia

Certain genetic patterns may predict response to CAR-T for acute lymphoblastic leukemia

Younger patients with acute lymphoblastic leukemia who do not respond to CD19-directed chimeric antigen receptor T-cell therapy exhibit certain gene regulation patterns that may be associated with treatment resistance, study results show.

News
April 12, 2022
3 min read
Save

CAR-T with, without mRNA vaccine shows promise for solid tumors

CAR-T with, without mRNA vaccine shows promise for solid tumors

Early data from a phase 1 trial showed encouraging clinical activity for an investigational chimeric antigen receptor T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.

News
April 09, 2022
2 min read
Save

Point-of-care CAR-T shows ‘promising’ efficacy, safety for B-cell non-Hodgkin lymphoma

Point-of-care CAR-T shows ‘promising’ efficacy, safety for B-cell non-Hodgkin lymphoma

Early phase 1 trial results using an investigational chimeric antigen receptor T-cell therapy manufactured at University of Colorado show encouraging efficacy for adults with relapsed or refractory B-cell non-Hodgkin lymphoma.

News
April 05, 2022
1 min read
Save

FDA grants fast track designation to CD33-directed CAR-T for acute myeloid leukemia

FDA grants fast track designation to CD33-directed CAR-T for acute myeloid leukemia

The FDA granted fast track designation to PRGN-3006 for the treatment of adults with relapsed or refractory acute myeloid leukemia.

News
April 04, 2022
4 min read
Save

FDA approves Yescarta as second-line therapy for large B-cell lymphoma

FDA approves Yescarta as second-line therapy for large B-cell lymphoma

The FDA approved axicabtagene ciloleucel as second-line treatment for adults with large B-cell lymphoma who are refractory to first-line chemoimmunotherapy or experienced disease relapse within 12 months of initial treatment.

News
March 31, 2022
6 min read
Save

Lack of awareness, limited sites hinder CAR-T trials for younger patients with cancer

Lack of awareness, limited sites hinder CAR-T trials for younger patients with cancer

The FDA’s approval of tisagenlecleucel in 2017 resulted in an explosion of research into chimeric antigen receptor T-cell therapies.

News
March 25, 2022
4 min read
Save

Next breakthrough for CAR T cells may come in acute myeloid leukemia

Next breakthrough for CAR T cells may come in acute myeloid leukemia

Commercially available chimeric antigen receptor T cells for acute myeloid leukemia could be just a few years away, according to a presenter at the inaugural Personalizing Pediatric Cancer Care Summit.

News
March 23, 2022
4 min read
Save

Investigational therapy for B-cell malignancies offers three targets in one CAR T cell

Investigational therapy for B-cell malignancies offers three targets in one CAR T cell

B-cell activating factor is a ligand protein, which makes it uniquely suited as a therapeutic option for the newly emerging class of multitargeted chimeric antigen receptor T-cell therapies.

View more